BET Protein Proteolysis Targeting Chimera (BETP-PROTACs) Exert Potent Activity Against Post-Myeloproliferative Neoplasm (MPN) Secondary (s)-AML Cells

被引：0
|
作者：
Saenz, Dyana [1 ]
Fiskus, Warren [1 ]
Manshouri, Taghi [1 ]
Mill, Christopher [1 ]
Sun, Baohua [1 ]
Verstovsek, Srdan [1 ]
Bhalla, Kapil [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2017年 / 17卷
关键词：
D O I：
10.1016/j.clml.2017.07.189
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MPN-231
引用
收藏
页码：S358 / S358
页数：1
相关论文
共 17 条
  • [1] BET protein proteolysis targeting chimera (BETP-PROTACs) exert more potent activity than BETP bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm (MPN) secondary (s) AML cells
    Saenz, Dyana T.
    Fiskus, Warren C.
    Raina, Kanak
    Manshouri, Taghi
    Coleman, Kevin G.
    Qian, Yimin
    Crew, Andrew P.
    Shen, Angela
    Mill, Christopher P.
    Sun, Baohua
    Kim, Misun
    Nowak, Agnieszka J.
    Verstovsek, Srdan
    Crews, Craig M.
    Bhalla, Kapil N.
    CANCER RESEARCH, 2017, 77
  • [2] Superior Lethal Activity of Novel BET Protein Proteolysis Targeting Chimera (BETP-PROTACs) Versus Betp Bromodomain Inhibitor (BETi) Against Post-Myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells
    Saenz, Dyana T.
    Fiskus, Warren
    Raina, Kanak
    Manshouri, Taghi
    Coleman, Kevin
    Winkler, Jim
    Qian, Yimin
    Crew, Andrew
    Shen, Angela
    Mill, Christopher P.
    Sun, Baohua
    Verstovsek, Srdan
    Crews, Craig
    Bhalla, Kapil N.
    BLOOD, 2016, 128 (22)
  • [3] Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells
    D T Saenz
    W Fiskus
    Y Qian
    T Manshouri
    K Rajapakshe
    K Raina
    K G Coleman
    A P Crew
    A Shen
    C P Mill
    B Sun
    P Qiu
    T M Kadia
    N Pemmaraju
    C DiNardo
    M-S Kim
    A J Nowak
    C Coarfa
    C M Crews
    S Verstovsek
    K N Bhalla
    Leukemia, 2017, 31 : 1951 - 1961
  • [4] Novel BET protein proteolysis-targeting chimera exerts superior lethal activity than bromodomain inhibitor (BETi) against post-myeloproliferative neoplasm secondary (s) AML cells
    Saenz, D. T.
    Fiskus, W.
    Qian, Y.
    Manshouri, T.
    Rajapakshe, K.
    Raina, K.
    Coleman, K. G.
    Crew, A. P.
    Shen, A.
    Mill, C. P.
    Sun, B.
    Qiu, P.
    Kadia, T. M.
    Pemmaraju, N.
    DiNardo, C.
    Kim, M-S
    Nowak, A. J.
    Coarfa, C.
    Crews, C. M.
    Verstovsek, S.
    Bhalla, K. N.
    LEUKEMIA, 2017, 31 (09) : 1951 - 1961
  • [5] Targeted Therapy with BET Protein and β Catenin Antagonists Against Ruxolitinib Resistant Post-Myeloproliferative Neoplasm (MPN) Secondary (s) AML Cells
    Saenz, Dyana T.
    Fiskus, Warren
    Manshouri, Taghi
    Qian, Yimin
    Raina, Kanak
    Saenz, David N.
    Mill, Christopher Peter
    Nowak, Agnieszka J.
    Sun, Baohua
    Verstovsek, Srdan
    Crews, Craig M.
    Bhalla, Kapil N.
    BLOOD, 2017, 130
  • [6] Novel BET Protein Proteolysis Targeting Chimeras (BETP-PROTACs)Exert Potent Single Agent and Synergistic Activity with Ibrutinib and Venetoclax Against Human Mantle Cell Lymphoma Cells
    Sun, Baohua
    Fiskus, Warren
    Zhang, Liang
    Raina, Kanak
    Coleman, Kevin
    Winkler, Jim
    Qian, Yimin
    Crew, Andrew
    Shen, Angela
    Saenz, Dyana T.
    Mill, Christopher P.
    Wang, Michael
    Crews, Craig
    Bhalla, Kapil N.
    BLOOD, 2016, 128 (22)
  • [7] BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells
    D T Saenz
    W Fiskus
    T Manshouri
    K Rajapakshe
    S Krieger
    B Sun
    C P Mill
    C DiNardo
    N Pemmaraju
    T Kadia
    S Parmar
    S Sharma
    C Coarfa
    P Qiu
    S Verstovsek
    K N Bhalla
    Leukemia, 2017, 31 : 678 - 687
  • [8] BET protein bromodomain inhibitor-based combinations are highly active against post-myeloproliferative neoplasm secondary AML cells
    Saenz, D. T.
    Fiskus, W.
    Manshouri, T.
    Rajapakshe, K.
    Krieger, S.
    Sun, B.
    Mill, C. P.
    DiNardo, C.
    Pemmaraju, N.
    Kadia, T.
    Parmar, S.
    Sharma, S.
    Coarfa, C.
    Qiu, P.
    Verstovsek, S.
    Bhalla, K. N.
    LEUKEMIA, 2017, 31 (03) : 678 - 687
  • [9] Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells
    Fiskus, Warren
    Manshouri, Taghi
    Birdwell, Christine
    Mill, Christopher P.
    Masarova, Lucia
    Bose, Prithviraj
    Kadia, Tapan M.
    Daver, Naval
    DiNardo, Courtney D.
    Borthakur, Gautam
    Khoury, Joseph D.
    Verstovsek, Srdan
    Bhalla, Kapil N.
    BLOOD CANCER JOURNAL, 2022, 12 (01)
  • [10] Efficacy of CDK9 inhibition in therapy of post-myeloproliferative neoplasm (MPN) secondary (s) AML cells
    Warren Fiskus
    Taghi Manshouri
    Christine Birdwell
    Christopher P. Mill
    Lucia Masarova
    Prithviraj Bose
    Tapan M. Kadia
    Naval Daver
    Courtney D. DiNardo
    Gautam Borthakur
    Joseph D. Khoury
    Srdan Verstovsek
    Kapil N. Bhalla
    Blood Cancer Journal, 12
12